title: Endostatin specifically targets both tumor blood vessels and lymphatic vessels.
abstract: Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, was first identified as a potent angiogenic inhibitor. The anti-angiogenic function of endostatin has been well documented during the past decade. Recently, several studies demonstrated that endostatin also inhibits tumor lymphangiogenesis and lymphatic metastasis. However, the exact mechanism that endostatin executes its anti-angiogenic and anti-lymphangiogenic functions remains elusive. In the current mini-review, we briefly summarize recent novel findings, including the functions of endostatin targeting not only angiogenesis but also lymphangiogenesis, and the underlying mechanism by which endostatin internalization regulates its biological functions.
authors.affiliation: National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Beijing 100084, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhuo
authors.forename: Yang
authors.initials: Y
authors.lastname: Chen
authors.forename: Xiaomin
authors.initials: X
authors.lastname: Song
authors.forename: Yongzhang
authors.initials: Y
authors.lastname: Luo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems; D043169:Endostatins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D042583:Lymphangiogenesis / Q000187:drug effects*; D008207:Lymphatic Metastasis / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins